ClinicalTrials.gg
Active, not recruitingNCT04262843Updated Oct 20, 2026

Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia

A Phase 2 interventional study of Cyclophosphamide and Fludarabine in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome, sponsored by City of Hope Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 12 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by City of Hope Medical Center · Phase 2, Interventional, and Treatment

How we know

Updated Oct 20, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
12 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 187 studies testing cyclophosphamide in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 28 open to participants now, 45 under way, 7 of them phase 3. Cyclophosphamide · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Enrollment
112th of 179
33 · median 47
Started
2020
with 2 others
Phase 2
104 of 187
15 open now
Primary completion
2027-05
later than 16 of 44 live
Registered
153rd of 187
by date
Lead sponsor
10 of 187
City of Hope Medical Center

Among the 187 studies testing cyclophosphamide in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 112th largest by enrollment of the 179 interventional ones that give a count, is one of 3 that started in 2020, is one of 104 in phase 2, reaches primary completion later than 16 of the 44 other live ones, and was the 153rd registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

28 of the 187 studies testing cyclophosphamide in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

23 more — sign in →

By country, each count listing its studies:

All 28 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 12 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing cyclophosphamide in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

This phase II trial studies how well total marrow and lymphoid irradiation works as a conditioning regimen before hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute leukemia. Total body irradiation can lower the relapse rate but has some fatal side effects such as irreversible damage to normal internal organs and graft-versus-host disease (a complication after transplantation in which donor's immune cells recognize the host as foreign and attack the recipient's tissues). Total body irradiation is a form of radiotherapy that involves irradiating the patient's entire body in an attempt to suppress the immune system, prevent rejection of the transplanted bone marrow and/or stem cells and to wipe out any remaining cancer cells. Intensity-modulated radiation therapy (IMRT) is a more recently developed method of delivering radiation. Total marrow and lymphoid irradiation is a method of using IMRT to direct radiation to the bone marrow. Total marrow and lymphoid irradiation may allow a greater dose of radiation to be delivered to the bone marrow as a preparative regimen before hematopoietic cell transplant while causing less side effects to normal organs than standard total body irradiation.

Read the detailed description

PRIMARY OBJECTIVE:

I. Evaluate the efficacy of the haploidentical hematopoietic cell transplantation (haploHCT) total marrow and lymphoid organ irradiation (TMLI), with high dose post-transplant cyclophosphamide (PTCy) as graft-versus host disease (GvHD) prophylaxis, as assessed by 1-year graft versus (vs) host disease-free relapse-free survival (GRFS) rate in each arm (Arm A: patients with acute myeloid leukemia [AML] or myelodysplastic syndrome [MDS] and Arm B: Patients with acute lymphoblastic leukemia [ALL]).

SECONDARY OBJECTIVES:

I. Estimate overall survival (OS), cumulative incidences of relapse/disease progression, and non-relapse mortality (NRM) in each arm at 100 days, and 1 year post-transplant.

II. Estimate rate of relapse and non-relapse mortality (NRM) at 1 year post-transplant.

III. Estimate rates of acute and chronic GvHD, infections, complete remission and neutrophil recovery.

IV. Describe and characterize cytokine release syndrome (CRS) post-haploidentical HCT with TMLI as conditioning regimen and PTCy as GvHD prophylaxis as assessed by incidence, frequency and severity.

V. Further evaluate the safety of this regimen by assessing:

Va. Adverse events: type, frequency, severity, attribution, time course, duration.

Vb. Complications: including acute/chronic GVHD, infection and delayed engraftment.

EXPLORATORY OBJECTIVES:

I. Characterize minimal residual disease from bone marrow aspirates and investigate the possible association between TMLI-based regimen and patient's disease status.

II. Describe the kinetics of immune cell recovery. III. Describe the kinetics of serum pro-inflammatory cytokines and GvHD biomarkers.

IV. Longitudinal and spatial assessment of TMLI effect on bone marrow environment.

V. Cellular and molecular assessment of TMLI effect on bone marrow environment and TMLI effect on the engraftment and disease relapse.

OUTLINE:

CONDITIONING: Patients receive fludarabine intravenously (IV) once daily (QD) on days -7 to -5, and undergo TMLI twice daily (BID) on days -4 to 0 in the absence of disease progression or unacceptable toxicity.

TRANSPLANT: Patients undergo hematopoietic cell transplantation on day 0.

GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV QD on days 3-4 in the absence of disease progression or unacceptable toxicity. Beginning on day 5, patients also receive granulocyte colony stimulating factor and tacrolimus/mycophenolate mofetil per institutional standard.

After completion of study treatment, patients are followed up twice weekly for the first 100 days post-transplant, twice monthly until 6 months post-transplant, monthly until patient discontinues immunosuppressive therapy, and then yearly for 2 years.

03

Conditions studied

  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • High Risk Myelodysplastic Syndrome
  • Myelodysplastic Syndrome
04

Who can participate

Ages eligible
12 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented of the participant and/or legally authorized representative
  • performance status >= 70
  • confirmed diagnosis of one the following:

    • Patients with acute myelogenous leukemia

      • In first complete remission (CR1) with intermediate or poor risk cytogenetics according to National Comprehensive Cancer Network (NCCN) guidelines for acute myeloid leukemia (AML) or European LeukemiaNet (ELN) 2017
      • In second complete remission (CR2) or third complete remission (CR3)
      • Patients with chemosensitive active disease
    • Patients with acute lymphocytic leukemia

      • In CR1 with poor risk cytogenetics:
    • For adults according to NCCN guidelines for acute lymphoblastic leukemia (ALL): Patients older than 40 year of age; with high white blood cell count (WBC) at diagnosis (>= 30,000 for B lineage or >= 50,000 for T lineage), or with high risk cytogenetics including: hypoploidy (\< 44 chromosomes); t(v;11q23): MLL rearranged; t(9;22) (q34;q11.2); complex cytogenetics (5 or more chromosomal abnormalities)
    • For pediatrics t(9;22), iAMP21loss of 13q, and abnormal 17p

      • In CR2 or CR3
      • Patients with chemosensitive active disease
    • Myelodysplastic syndrome in high-intermediate (int-2) and high risk categories by International Prognostic Scoring System (IPSS) or revised (R)-IPSS
  • Total =\< 2 X (ULN) (unless has Gilbert's disease) (to be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)
  • of >= 60 mL/min per 24 hour urine test or the Cockcroft-Gault formula (to be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)
  • measured by echocardiogram or multigated acquisition scan (MUGA) >= 50% (to be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)

    • Note: To be performed within 28 days prior to day 1 of protocol therapy
  • If able to perform pulmonary function tests: (FEV1), forced vital capacity (FVC) and carbon monoxide diffusing capability test (DLCO) (diffusion capacity) >= 50% of predicted (corrected for ). If unable to perform pulmonary function tests: oxygen (O2) saturation > 92% on room air

    • Note: To be performed within 28 days prior to day 1 of protocol therapy
  • Seronegative for (HIV) antigen (Ag)/antibody (Ab) combo, virus (HCV), active virus (HBV) (surface antigen negative), and syphilis (rapid plasma reagin [RPR]) (to be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)

    • If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed
  • Meets other institutional and federal requirements for infectious disease titer requirements

    • Note: Infectious disease testing to be performed within 28 days prior to Day 1 of protocol therapy
  • Women of (WOCBP): negative urine or serum pregnancy test

    • If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  • Agreement by females and males of childbearing potential* to use an effective method of or abstain from heterosexual activity for the course of the study through at least 6 months after the last dose of protocol therapy

    • Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)
  • The recipient must have a related donor genotypically human leukocyte antigen (HLA)-A, B,C and DRB1 loci haploidentical to the recipient
  • No HLA matched sibling or matched unrelated donor is available
  • Patients should be off all previous intensive therapy, chemotherapy or radiotherapy for 3 weeks prior to commencing therapy on this study

    • (NOTE: Low dose chemotherapy or maintenance chemotherapy given within 7 days of planned study enrollment is permitted. These include: Hydroxyurea, 6-meraptopurine, oral methotrexate, vincristine, oral etoposide, and tyrosine kinase inhibitors [TKIs]. FLT-3 inhibitors such as sorafenib, crenolanib, midostaurin can also be given up to 3 days before conditioning regimen.)
  • DONOR: The donor must be examined and have specific tests performed according to existing institutional guidelines to evaluate his/her candidacy as a donor including the following:
  • DONOR: Age =\< 60 years of age
  • DONOR: For younger donors, no more than 20 mL bone marrow may be harvested per kg of donor body weight
  • DONOR: Medical history and physical examination confirm good health status as defined by institutional standards
  • DONOR: Seronegative for HIV Ag, HIV 1+2 Ab, HTLV I/II Ab, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb) (IgM and IgG), HCV Ab, RPR for syphilis within 30 days of apheresis collection
  • DONOR: Genotypically haploidentical as determined by HLA typing, preferably a nonmaternal HLA haploidentical relative due to data of high incidence of graft failure with use of maternal HLA haploidentical cells. Eligible donors include biological parents, siblings or half siblings, or children
  • DONOR: Female donors of child-bearing potential must have a negative serum or urine beta-human chorionic gonadotropin (HCG) test within seven days of mobilization
  • DONOR: The donor must have been informed of the nature of this study and have signed a consent form in accordance with Federal Guidelines and the guidelines of the participating institution
  • DONOR: Selection of a haploidentical donor will require absence of pre-existing donor-directed anti-HLA antibodies in the recipient

Exclusion criteria

Exclusion Criteria:

  • Patients should not have any uncontrolled illness including ongoing or active bacterial, viral or fungal infection
  • Patient may not be receiving any other agents or concurrent biological, intensive chemotherapy or radiation therapy for the previous three weeks from conditioning

    • (NOTE: Low dose chemotherapy or maintenance chemotherapy given within 7 days of planned study enrollment is permitted. These include: Hydroxyurea, 6-meraptopurine, oral methotrexate, vincristine, oral etoposide, and tyrosine kinase inhibitors [TKIs]. FLT-3 inhibitors such as sorafenib, crenolanib, midostaurin can also be given up to 3 days before conditioning regimen.)
  • Herbal medications dependency
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent
  • No intercurrent illness or other (other than non-melanoma skin cancer)
  • Active infection requiring antibiotics
  • Known history of immunodeficiency virus () or or infection
  • Females only: Pregnant or breastfeeding
  • Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
  • Patients who had a prior or allogeneic transplant
  • Patients who had prior radiation therapy of more than 20% of bone marrow containing areas or to any area exceeding 2000 cGy
  • Patients with HLA-matched or partially matched (7/8 or 8/8) related or fully matched unrelated donor available to donate
  • Patients who have received more than 3 prior regimens, where the regimen intent was to induce remission
  • Patients with treatment history including anti-CD33 monoclonal antibody therapy (e.g., SGN-CD33 or Mylotarg)
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
  • DONOR: Evidence of active infection
  • DONOR: Medical or physical reason which makes the donor unlikely to tolerate or cooperate with growth factor therapy and leukapheresis
  • DONOR: Factors which place the donor at increased risk for complications from leukapheresis or granulocyte colony-stimulating factor (G-CSF) therapy
  • DONOR: HIV positive
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Treatment (fludarabine, TMLI, HCT, cyclophosphamide)

    CONDITIONING: Patients receive fludarabine IV QD on days -7 to -5, and undergo TMLI BID on days -4 to 0 in the absence of disease progression or unacceptable toxicity. TRANSPLANT: Patients undergo hematopoietic cell transplantation on day 0. GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV QD on days 3-4 in the absence of disease progression or unacceptable toxicity. Beginning on day 5, patients also receive granulocyte colony stimulating factor and tacrolimus/mycophenolate mofetil per institutional standard.

    Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Fludarabine Phosphate · Biological: Granulocyte Colony-Stimulating Factor · Procedure: Hematopoietic Cell Transplantation · Procedure: Intensity-Modulated Radiation Therapy · Drug: Mycophenolate Mofetil · Drug: Tacrolimus

Interventions

  • Given IV

    Also known as: (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719

  • Given IV

    Also known as: Fluradosa

  • Given IV

    Also known as: 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586

  • Growth factor therapy

    Also known as: Colony Stimulating Factor 3, Colony-Stimulating Factor (Granulocyte), Colony-Stimulating Factor 3, CSF3, G CSF, G-CSF, Granulocyte Colony Stimulating Factor, Pluripoietin

  • ProcedureHematopoietic Cell Transplantation

    Undergo hematopoietic cell transplantation

    Also known as: HCT, Hematopoietic Stem Cell Transplantation, HSCT, Stem Cell Transplant, stem cell transplantation

  • ProcedureIntensity-Modulated Radiation Therapy

    Undergo TMLI

    Also known as: IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy

  • DrugMycophenolic AcidStudies of Mycophenolic AcidMycophenolic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Immunosuppressive therapy

    Also known as: Cellcept, MMF

  • Immunosuppressive therapy

    Also known as: FK 506, Fujimycin, Hecoria, Prograf, Protopic

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Evaluated using the Bearman scale and National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: Up to day 100

  2. Graft-versus-host disease (GvHD) free relapse-free survival

    Time frame: Time from start of protocol therapy to grade 3-4 acute GvHD, chronic GvHD requiring systemic treatment, death, relapse/progression, or last follow-up, whichever comes first, assessed up to 2 years post-transplant

Secondary outcomes

  1. Overall survival

    Time frame: Time from start of protocol therapy to death from any cause, or last follow-up, whichever comes first, assessed up to 2 years post-transplant

  2. Relapse-free survival

    Time frame: Time from the start of protocol therapy to the date of death, disease relapse, or last follow-up, whichever comes first, assessed up to 2 years post-transplant.]

  3. Time to relapse/progression

    Time frame: Time from the start of protocol therapy to death, disease relapse or progression, or last follow-up, whichever comes first, assessed up to 2 years post-transplant

  4. Non-relapse mortality

    Time frame: Time from start of therapy until non-disease related death, or last follow-up, whichever comes first, assessed up to 2 years post-transplant

  5. Incidence of adverse events that meet grade 3, 4, or 5 per CTCAE version 5.0

    Time frame: From day -9 to day -1, from day 0 to day 30, and day 31 to day 100 post-transplant

  6. Incidence of acute GvHD of grades 2-4 and 3-4

    Time frame: From date of stem cell infusion to documented/biopsy proven acute GVHD onset date (within the first 100 days post-transplant)

  7. Incidence of chronic GvHD

    Time frame: From approximately 80-100 days post-transplant to the documented/biopsy proven chronic GvHD onset date

  8. Incidence of infection

    Time frame: From day 0 to day 100 post-transplant

  9. Complete remission proportion

    Time frame: At day 30

  10. Rate of neutrophil recovery

    Measured from stem cell infusion to the first to three consecutive days with neutrophil count greater than 0.5 x 10\^9/l.

    Time frame: Up to 2 years

  11. Incidence of cytokine release syndrome

    Defined and graded per American Society for Transplantation and Cellular Therapy (ASTCT) criteria.

    Time frame: Up to 2 years

Other outcomes

  1. Minimal residual disease

    Assessed from bone marrow aspirates.

    Time frame: At day 30, 100, and 180 days, and 1 year post-transplant

  2. Immune cell recovery

    Immunophenotyping with lymphocyte subsets by flow cytometry, including but not limited to the following cell markers: CD4, CD8, CD56, CD16, etc.

    Time frame: Up to 2 years

  3. GvHD biomarker analysis

    Will be done by standard enzyme-linked immunosorbent (ELISA) assays.

    Time frame: Up to 2 years

  4. Pro-inflammatory cytokine analysis

    Will be done using standard ELISA assays.

    Time frame: Up to 2 years

  5. Effect of TMLI on bone marrow environment

    Longitudinal assessment swill be done by dual energy computed tomography (DECT), water-fat magnetic resonance imaging (wfMRI) imaging. Biological assessment of bone marrow samples will be done by flow cytometry, colony forming assay, and immunohistochemistry studies.

    Time frame: Up to 2 years

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for May 2027, 87 months after the start.

Of 209 non-industry phase 2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 120. This study's planned 87 months is above that.

Counting every sponsor, half of 227 studies reached it within 74 months; a quarter within 42 and three quarters within 120.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2020
First posted
Feb 10, 2020
StartActual
Feb 6, 2020
Primary completionEst.
May 11, 2027
CompletionEst.
May 11, 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Feb 7, 2020→Feb 6, 2020
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Start date Feb 7, 2020→Feb 6, 2020
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04262843
Responsible party
Sponsor
First posted
Feb 10, 2020
Start date
Feb 6, 2020
Primary completion
May 11, 2027 (estimated)
Completion
May 11, 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Monzr M Al Malki
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclophosphamide · Fludarabine · Fludarabine phosphate · Granulocyte Colony-Stimulating Factor · Mycophenolic Acid · Tacrolimus

Start the discussion